I''ll put up a few posts to try and give a better picture of...

I''ll put up a few posts to try and give a better picture of what I saw and heard in the US.
SHC isn't without risk.( disclaimer out of the way)
I just don 't think from the posts I've read people get the scale of what's about to come.

(series because my iPad is dropping out every now and again. )

An analyst described to me as the most influential with Lazards in the Medical Tech field asked many questions of Dr Abrahams a real leader in cardiology. The analyst knew the answers he just wanted the rest of the room to hear the answers. The analyst and Abrahams were discussing trials as far back as 2004? That they both had a common interest in and knowledge of of. The analyst was being really supportive of SHC.

Later Abrahams was asked after an hour+ of questioning by Wall Street+ others funds/analyst etc and discussion about results and next trial by me "would he enthusiastically recommend C-Pulse for his patients ?"
His reply was stunning, Abrahams said he "would Reccomend C-Pulse for ALL his NYHA Class 3 patients".

I think all of us who follow SHC realise what a mind boggling market he is implying.


for the trial